2020 Outlook: State Lawmakers Tee Up Bills on PBMs, Drug Pricing This Year

State lawmakers will continue to focus on the cost of prescription drugs as the 2020 legislative season gets underway, potentially advancing measures to require the disclosure of manufacturer drug pricing information and bills to limit or eliminate the role PBMs play in state Medicaid programs.

However, the abbreviated length of the election-year legislative sessions, plus some unexpected hiccups in states that already have passed bills on those issues, could limit how much actually gets done at the state level in 2020, legislative observers say.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

insulin-injection
April 11

Current Market Access to GLP-1s

READ MORE
ruler
April 11

Wegovy’s New Indication Turns Up Heat on Employers Sweating GLP-1 Costs

READ MORE
cvs-health-building
April 11

Big Three PBMs Cover Opill With $0 Cost Sharing for Most Commercial Plans

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today